Dr. Martin McMahon and his research group study the genetic mutations that contribute to lung cancer. About 30% of lung cancers can now be treated based on the disease’s specific genetics. McMahon is hopeful that each subset of lung cancer will soon have its own precision treatment.
Huntsman Cancer Institute began in 1995 with an empty lot and a dream full of promise. Twenty-two years later, HCI is opening a major expansion that will double its research capacity.
On September 7, 2016, National Cancer Institute (NCI) Acting Director Douglas Lowy, MD, accepted the recommendations of the Cancer Moonshot Blue Ribbon Panel (BRP) on a set of scientific approaches to accelerate progress in cancer research. An overview of the report was published in the journal Science.
When Kiera Jorgensen was diagnosed with cancer at the age of 19, she fought not only sarcoma, but also a deadly mystery that had loomed over her family for generations. Now years out of treatment, Kiera has answers and is conducting research to help families like hers better understand a rare genetic mutation.
Huntsman Cancer Institute (HCI) at the University of Utah participated in a national summit on the Cancer Moonshot initiative on June 29, 2016. The Cancer Moonshot Summits were organized at the request of Vice President Joe Biden, and more than 270 organizations hosted summits that brought together patients and survivors, researchers, physicians, advocates, philanthropists, and data and technology experts to brainstorm ways of speeding up progress in cancer prevention, diagnosis, treatment, and care over the next five years—and to ultimately end cancer as we know it.
Inheriting a mutation in the APC gene leads to a nearly 100% lifetime risk of colorectal cancer. While colon cancer can be kept at bay by removing the large intestine, these patients also have up to a 15% risk of getting cancer in the small intestine, which is the leading cause of cancer death in this patient group. A new study published in the Journal of the American Medical Association (JAMA) has identified the first prevention treatment for these patients, a two-drug combination that significantly reduces the number and size of precancerous polyps in the small intestine.